Modality
ADC
MOA
KRASG12Ci
Target
LAG-3
Pathway
Lipid Met
AS
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
~Jan 2022
→ ~Apr 2023
Phase 3
Jul 2023
→ Oct 2030
Phase 3Current
NCT08512494
609 pts·AS
2025-08→2025-09·Terminated
NCT07407748
932 pts·AS
2023-07→2027-02·Active
NCT07384166
1,567 pts·AS
2024-06→2030-10·Active
3,108 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-09-097mo agoPh3 Readout· AS
2026-11-288mo awayPh1 Dose Esc· AS
2027-02-1611mo awayPh3 Readout· AS
2030-10-054.5y awayPh3 Readout· AS
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Active
P3
Active
P3
Termina…
Catalysts
Ph3 Readout
2025-09-09 · 7mo ago
AS
Ph1 Dose Esc
2026-11-28 · 8mo away
AS
Ph3 Readout
2027-02-16 · 11mo away
AS
Ph3 Readout
2030-10-05 · 4.5y away
AS
ActiveTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08512494 | Phase 3 | AS | Terminated | 609 | CR |
| NCT07407748 | Phase 3 | AS | Active | 932 | ORR |
| NCT07384166 | Phase 3 | AS | Active | 1567 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ |